...A.R.J Girbes; A.R. Milner; B.V. McCloskey; J.H. Zwaveling; D.J. van Veldhuisen; J.G. Zijlstra; K.I. Lie In a prospective open study we evaluated whether intravenous dopamine infusions can be safely switched to enterally administered ibopamine in dopamine-dependent patients. Six patients defined...

...F.X. Kleber; G.V. Sabin; U. Thyroff-Friesinger; B. Cabell; D. Glogar Ibopamine is an active dopamine analogue leading to improved renal perfusion and afterload reduction in heart failure. This report describes casuistic experiences in patients with severe heart failure awaiting heart...

...) and of ibopamine (150–300 mg/day) on exercise testing, symptoms and subjective feeling of wellbeing, in 150 CHF elderly patients (mean age 75 years) under treatment with digitalis and/or diuretics. During an additional open follow-up of approximately 1.5 years, morbid events and deaths were also recorded...

...Krzysztof Skwarski; Annie Barratt; William MacNee We have studied the effects of ibopamine, an oral dopamine derivative, on pulmonary hemodynamics and blood gas values when given as a single oral dose (100 mg) to patients with severe hypoxic chronic obstructive pulmonary disease. A small...

...H. Itoh; K. Taniguchi; T. Tsujibayashi; A. Koike; Y. Sato; S. Nakamura To evaluate the attenuation of the effectiveness of long-term ibopamine therapy, ibopamine was administered in single doses of 100 and 200 mg to 10 patients with chronic heart disease. The hemodynamic studies using Swan-Ganz...

...F.X. Kleber; U. Thyroff-Friesinger This multicentre, double-blind, double-dummy, randomised parallel group study in 247 patients with mild chronic congestive heart failure compared the efficacy and tolerability of ibopamine, hydrochlorothiazide (HCTZ), ibopamine plus HCTZ and placebo during an 8...

...G.V. Marchetti This review summarizes the results obtained with ibopamine on anaesthesized dogs. Ibopamine is a dopamine-related drug active by oral route, namely the diisobutyric ester of N-methyl-dopamine. Ibopamine is able to activate dopamine specific and adrenergic receptors in the heart...

...F.X. Kleber; U. Thyroff-Friesinger We describe a randomized double-blind 4-week study on the efficacy of monotherapy with ibopamine 200 mg b.i.d. in comparison to placebo and open titrated digoxin in patients with mild congestive heart failure NYHA class I and II. A total of 60 patients (22 males...

...C. Holubarsch; H. Just Before a new drug can be recommended for treatment of chronic heart failure, efficacy and safety have to be fulfilled. In this paper, the safety aspect of ibopamine, a congener of dopamine, is investigated by reviewing the available reports on this drug. A trend towards...

...K. Taniguchi; T. Tsujibayashi; H. Itoh Fifteen congestive heart failure patients (NYHA: class III or IV) were enrolled in the study and were classified into two groups. Six patients (group I) received combined therapy by nitroglycerin tape (5 mg) and ibopamine (100 mg), while the remaining 9...

...A. Azzolinï; E. Guffanti; M. Ronzitti; L. Tantalo; A. Colantoni; C. Pizzorni This double-blind, randomized, multicenter clinical study assessed the efficacy and safety of ibopamine 100 mg t.i.d. as monotherapy vs. placebo in 52 patients with mild chronic heart failure aged over 60 years during a 12...

...S. Caponnetto; V. Terrachinï; C. Canale; F. Bruzzone; M.A. Masperone; L. Pastorino; L. Licciardello; G.V. Marchetti A group of 30 patients with II-III NYHA class cardiac insufficiency was treated with ibopamine in association with other drugs for a 6-month period. The patients were submitted...

... alternative. Ibopamine is an orally active dopaminergic substance and acts mainly as a vasodilator in patients with heart failure. According to published investigations on ibopamine in heart failure, this drug does not seem to have a proarrhythmic effect. 12 11 2008 © 1990 S. Karger AG, Basel...

...L. Benzi; F. Sabino; A.M. Ciccarone; P. Cecchetti; G. Di Ciannï; V. Cicchetti; R. Navalesï Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure who were studied after 3 weeks of placebo and ibopamine (100 mg t.i.d...

...P. Marchetti; F. Sabino; R. Giannarelli; A. DiCarlo; V. Cicchettï; R. Navalesi Twelve outpatients with type II diabetes mellitus and mild clinical signs and history of cardiac failure were studied to assess the effects of ibopamine on glucose and lipid metabolism. For the assessment of cardiac...

...J. López-Sendón Ibopamine is a new, orally active dopamine-like drug with inotropic and vasoac-tive properties. With a predominant action on dopaminergic (DA) and β-receptors, ibopamine increases cardiac output, reduces peripheral vascular resistances and increases renal blood flow, exerting...

...M. Wehling; J. Zimmermann; K. Theisen Ibopamine is a novel oral dopamine analogue with vasodilatory, positive inotropic and diuretic effects. In a double-blind, randomized study, the drug was investigated in 12 patients (mean age 49 ± 10 years, 8 male, 4 female) with mild or moderate heart failure...

...W.-D. Bussmann; K. Wienhöfer; R. Frik Ibopamine is an orally effective derivative of dopamine capable of eliciting peripheral and renal vasodilating activity and positive inotropic action. The compound is a prodrug which is enzymatically converted by plasma and peripheral tissues esterases...